Table 1.
RA patient baseline demographics, medication history, and disease severity
| Demographics | Cohort I | Cohort II | Combined |
| Total, n | 8 | 10 | 18 |
| Enrollment by country | |||
| Bosnia | 3 | 0 | 3 |
| Croatia | 2 | 0 | 2 |
| The Netherlands | 3 | 10 | 13 |
| Mean age in years (range) | 55 (36–69) | 48 (36–56) | 51 (36–69) |
| Sex, % female | 50 | 100 | 78 |
| Ethnicity, % Caucasian | 88 | 100 | 94 |
| Mean no. of years since RA diagnosis (SD) | 9.9 (5.7) | 11.8 (6.3) | 11.0 (5.9) |
| No. rheumatoid factor-positive patients (%) | 7 (88) | 5 (50) | 12 (67) |
| No. anti-citrullinated peptide Ab+ patients (%) | 6 (75) | 6 (60) | 12 (67) |
| No. patients receiving prior nonbiologic disease-modifying antirheumatic drugs (%) | |||
| 0 drugs | 1 (13) | 1 (10) | 2 (11) |
| 1 drug | 2 (25) | 3 (30) | 5 (28) |
| 2 drugs | 2 (25) | 2 (20) | 4 (22) |
| 3 or more drugs | 3 (37) | 4 (40) | 7 (39) |
| No. patients receiving prior biologic disease-modifying antirheumatic drugs (%) | |||
| 0 drugs | 3 (38) | 0 | 3 (17) |
| 1 drug | 4 (50) | 0 | 4 (22) |
| 2 drugs | 1 (12) | 0 | 1 (6) |
| 3 drugs | 0 | 3 (30) | 3 (17) |
| 4 drugs | 0 | 4 (40) | 4 (22) |
| 5 drugs | 0 | 2 (20) | 2 (11) |
| 6 drugs | 0 | 1 (10) | 1 (6) |
| DAS28-CRP (SD) | 6.05 (0.87) | 5.94 (0.72) | 5.99 (0.77) |
| High-sensitivity CRP, mg/L (SD) | 17.5 (10.0) | 17.5 (18.5) | 17.5 (14.9) |